These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 19707445)

  • 1. Denosumab: an investigational drug for the management of postmenopausal osteoporosis.
    Lewiecki EM
    Biologics; 2008 Dec; 2(4):645-53. PubMed ID: 19707445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RANK ligand inhibition with denosumab for the management of osteoporosis.
    Lewiecki EM
    Expert Opin Biol Ther; 2006 Oct; 6(10):1041-50. PubMed ID: 16989586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab: a promising drug for the prevention and treatment of osteoporosis.
    Lewiecki EM
    Womens Health (Lond); 2006 Jul; 2(4):517-25. PubMed ID: 19803959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Denosumab in postmenopausal osteoporosis: what the clinician needs to know.
    Lewiecki EM
    Ther Adv Musculoskelet Dis; 2009 Feb; 1(1):13-26. PubMed ID: 22870424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis.
    Lewiecki EM
    Drug Healthc Patient Saf; 2011; 3():79-91. PubMed ID: 22279412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of osteoporosis with denosumab.
    Lewiecki EM
    Maturitas; 2010 Jun; 66(2):182-6. PubMed ID: 20236778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denosumab for joints and bones.
    Lewiecki EM
    Curr Rheumatol Rep; 2009 Jul; 11(3):196-201. PubMed ID: 19604464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denosumab update.
    Lewiecki EM
    Curr Opin Rheumatol; 2009 Jul; 21(4):369-73. PubMed ID: 19424068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis].
    Varenna M; Gatti D
    Reumatismo; 2010; 62(3):163-71. PubMed ID: 21052563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denosumab--an emerging treatment for postmenopausal osteoporosis.
    Lewiecki EM
    Expert Opin Biol Ther; 2010 Mar; 10(3):467-76. PubMed ID: 20095877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Denosumab: RANKL inhibition in the management of bone loss.
    Hamdy NA
    Drugs Today (Barc); 2008 Jan; 44(1):7-21. PubMed ID: 18301800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
    Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
    Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical use of denosumab for the treatment for postmenopausal osteoporosis.
    Lewiecki EM
    Curr Med Res Opin; 2010 Dec; 26(12):2807-12. PubMed ID: 21050058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging treatments for postmenopausal osteoporosis - focus on denosumab.
    Geusens P
    Clin Interv Aging; 2009; 4():241-50. PubMed ID: 19554095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab in postmenopausal women with low bone mineral density.
    McClung MR; Lewiecki EM; Cohen SB; Bolognese MA; Woodson GC; Moffett AH; Peacock M; Miller PD; Lederman SN; Chesnut CH; Lain D; Kivitz AJ; Holloway DL; Zhang C; Peterson MC; Bekker PJ;
    N Engl J Med; 2006 Feb; 354(8):821-31. PubMed ID: 16495394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
    Lewiecki EM; Miller PD; McClung MR; Cohen SB; Bolognese MA; Liu Y; Wang A; Siddhanti S; Fitzpatrick LA;
    J Bone Miner Res; 2007 Dec; 22(12):1832-41. PubMed ID: 17708711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is denosumab better than alendronate in the treatment of osteoporosis?
    Lewiecki EM
    Nat Clin Pract Rheumatol; 2009 Feb; 5(2):72-3. PubMed ID: 19092832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on denosumab treatment in postmenopausal women with osteoporosis.
    Min YK
    Endocrinol Metab (Seoul); 2015 Mar; 30(1):19-26. PubMed ID: 25827453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New and emerging concepts in the use of denosumab for the treatment of osteoporosis.
    Lewiecki EM
    Ther Adv Musculoskelet Dis; 2018 Nov; 10(11):209-223. PubMed ID: 30386439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are drug holidays a safe option in treatment of osteoporosis? - Insights from an in silico mechanistic PK-PD model of denosumab treatment of postmenopausal osteoporosis.
    Martínez-Reina J; Calvo-Gallego JL; Pivonka P
    J Mech Behav Biomed Mater; 2021 Jan; 113():104140. PubMed ID: 33080564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.